In a report issued on February 21, Ahu Demir from Noble Financial reiterated a Buy rating on TherapeuticsMD (TXMD), with a price target of $10.00. The company’s shares closed last Monday at $2.06, close to its 52-week low of $1.82.
According to TipRanks.com, Demir is ranked #5138 out of 5976 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for TherapeuticsMD with a $9.25 average price target, which is a 330.2% upside from current levels. In a report issued on February 21, H.C. Wainwright also reiterated a Buy rating on the stock with a $6.00 price target.
See today’s analyst top recommended stocks >>
Based on TherapeuticsMD’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $49.44 million. In comparison, last year the company had a GAAP net loss of $39.39 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
